Dear Colleagues,

Despite unsuccessful eradication attempts, control efforts to avoid infections, and artemisinin-based therapies, the global burden of malaria remains high, with 430,000 deaths every year and 200 million cases. Unfortunately, children represent a high proportion of new diagnoses.

Over the last few years, renewed attempts to control the disease have reduced the prevalence of malaria by over 50%, raising the prospect that elimination and perhaps eradication may be a long-term possibility.

Achievement of this goal requires the development of new tools, including efficacious vaccines as well as a precise understanding of the pathophysiology and biology of the parasite, and especially novel antimalarial drugs and combinations which could safely ensure the rapid clearance of infection as well as a durable cure without recurrence. In addition, the development of resistance to past and present anti-malarial drugs, especially artemisinin-based regimes, highlights the need for continued research to stay one step ahead, specifically to treat severe complications such as cerebral malaria.

Multiple approaches to develop new antimalarial medications, ranging from modifications of existing agents to the design of novel agents targeting novel targets, already exist.

Modern advances in parasite biology knowledge, along with the availability of various genomic techniques, represent several novel targets for the elaboration of new therapies.

This Special Issue aims to collect original articles, literature reviews, and case reports/case series on emerging treatment options against malaria, with particular interest on new compounds, either experimental or under research, and drug combinations.

Dr. Nicolò Musso
Dr. Andrea Marino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Malaria
• antimalarial drugs
• severe malaria
• resistant malaria